title: An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels.
authors.affiliation: Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany.
authors.forename: Thies
authors.initials: T
authors.lastname: Rösner
authors.forename: Stefanie
authors.initials: S
authors.lastname: Derer
authors.forename: Christian
authors.initials: C
authors.lastname: Kellner
authors.forename: Michael
authors.initials: M
authors.lastname: Dechant
authors.forename: Stefan
authors.initials: S
authors.lastname: Lohse
authors.forename: Gestur
authors.initials: G
authors.lastname: Vidarsson
authors.forename: Matthias
authors.initials: M
authors.lastname: Peipp
authors.forename: Thomas
authors.initials: T
authors.lastname: Valerius
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000276:immunology* / Q000627:therapeutic use; D018951:Antigens, CD20 / Q000097:blood / Q000276:immunology*; D000970:Antineoplastic Agents / Q000276:immunology* / Q000627:therapeutic use; D003171:Complement Pathway, Classical; D003165:Complement System Proteins / Q000276:immunology* / Q000378:metabolism; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D015973:Gene Expression Regulation, Leukemic / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology* / Q000627:therapeutic use; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D007074:Immunoglobulin G; D000069283:Rituximab; D003165:Complement System Proteins